Answers are grounded in this paper and cite their sources.
Examining drug development efforts reveals challenges in translating successes into effective treatments for higher-risk MDS.
Examining the history and evolution of investigational pharmacotherapy in higher-risk MDS may help identify where efforts to translate early phase successes into successful phase III trials have faltered. The expanding biological knowledge base and the design of better therapies will hopefully pave the way for future therapeutic breakthroughs.
No takes yet. Share an insight, caveat, or question.
Mina et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: